Bhaumik Suniti, Basu Rajatava, Sen Subha, Naskar Kshudiram, Roy Syamal
Department of Immunology, Indian Institute of Chemical Biology (IICB), 4, Raja S.C. Mullick Road, Jadavpur, Calcutta, 700032, WB, India.
Vaccine. 2009 Feb 25;27(9):1306-16. doi: 10.1016/j.vaccine.2008.12.053. Epub 2009 Jan 20.
As vaccine potential of cross-species protection by a candidate antigen is less explored, in this study we compared cross-specific protective efficacy of Kinetoplastid Membrane Protein-11 (KMP-11) as a DNA vaccine alone and in conjunction with exogenous IL-12 administration in experimental BALB/c model against two most widely prevalent forms of clinical diseases caused by Leishmania major (LM) and Leishmania donovani (LD). Whereas, KMP-11 DNA vaccination alone showed significant potential in terms of resolution of splenic and hepatic parasite burden against virulent LD challenge, it showed considerably less efficacy (<70% reduction) against virulent LM challenge in terms of presence of parasite in lymph node. Remarkably exogenous IL-12 administration in the form of IL-12 p35/p40 expression vectors or recombinant protein along with KMP-11 DNA had exactly opposing effect on protection against LM and LD. Exogenous IL-12 administration significantly increased residual LD-burden but enhanced the protective efficacy of KMP-11 DNA vaccine against LM compared to KMP-11 immunization alone. Elucidation of effector mechanism showed KMP-11 DNA induced protection against LD was associated with the generation of mixed Th1/Th2 response, while KMP-11/IL-12-induced comparable protection against LM was associated with high IgG2a titre indicative of a polarized Th1 response. Exogenous IL-12 administration resulted in robust gamma interferon (IFN-gamma) production and suppression of IL-4 from CD4+ T cell against both LM and LD. Nevertheless protective immune response was only compromised against LD infection where frequency of anti-KMP-11 CTL response was significantly reduced after exogenous IL-12 administration. Our study provides a comparative evaluation of effector mechanisms in the assessment of cross-specific protection by KMP-11 and KMP-11/IL-12 immunization against these two prevalent forms of leishmaniasis.
由于候选抗原跨物种保护的疫苗潜力尚未得到充分探索,在本研究中,我们在实验性BALB/c模型中比较了动质体膜蛋白11(KMP-11)作为单独的DNA疫苗以及与外源性IL-12联合给药时,针对由硕大利什曼原虫(LM)和杜氏利什曼原虫(LD)引起的两种最广泛流行的临床疾病形式的交叉特异性保护效果。虽然单独的KMP-11 DNA疫苗接种在解决脾脏和肝脏寄生虫负荷以应对强毒力LD攻击方面显示出显著潜力,但就淋巴结中寄生虫的存在而言,其对强毒力LM攻击的效果要低得多(减少<70%)。值得注意的是,以IL-12 p35/p40表达载体或重组蛋白形式与KMP-11 DNA一起给予外源性IL-12,对针对LM和LD的保护产生了完全相反的效果。外源性IL-12给药显著增加了残余LD负荷,但与单独的KMP-11免疫相比,增强了KMP-11 DNA疫苗对LM的保护效果。效应机制的阐明表明,KMP-11 DNA诱导的针对LD的保护与混合Th1/Th2反应的产生有关,而KMP-11/IL-12诱导的针对LM的类似保护与高IgG2a滴度有关,表明存在极化的Th1反应。外源性IL-12给药导致针对LM和LD均产生强大 的γ干扰素(IFN-γ)并抑制CD4+ T细胞产生IL-4。然而,仅针对LD感染,保护性免疫反应受到损害,在外源性IL-12给药后,抗KMP-11 CTL反应的频率显著降低。我们的研究提供了对效应机制的比较评估,以评估KMP-11和KMP-11/IL-12免疫针对这两种流行的利什曼病形式的交叉特异性保护。